A bill for an act relating to insurance coverage for prescription drugs used to treat substance use disorders.
Impact
If enacted, SF413 would significantly influence state insurance regulations by expanding the obligations of health carriers to provide favorable coverage terms for treatments related to substance use disorders. The legislation stipulates that the coverage for these medications cannot be less favorable than that offered for general physical illnesses, which would help in eliminating disparities in treatment coverage and potentially improve health outcomes for patients seeking help.
Summary
Senate File 413 is legislation aimed at ensuring comprehensive insurance coverage for prescription drugs that treat substance use disorders. The bill mandates that health insurance policies offering coverage for prescription drugs must include all medications approved by the United States Food and Drug Administration specifically for treating these disorders. This requirement seeks to address gaps in current insurance practices, where certain medications may not be covered adequately, thereby impacting treatment accessibility for individuals struggling with substance use issues.
Contention
The bill's adoption may prompt discussions among stakeholders regarding its implications for insurers and healthcare providers. Some critics may argue about the financial implications for insurance companies, which could necessitate adjustments in their coverage policies and premium structures. Proponents, however, are likely to highlight the necessity of such coverage in combating the widespread issues associated with substance use disorders, emphasizing the greater public health benefits that could arise from increased access to treatment through more comprehensive insurance provisions.
A bill for an act relating to health insurance coverage for specified pediatric autoimmune neuropsychiatric disorders and postinfectious autoimmune encephalopathy.
A bill for an act relating to health insurance coverage for specified pediatric autoimmune neuropsychiatric disorders and postinfectious autoimmune encephalopathy.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.